1. Ostrom QT, Price M, Neff C, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019. Neuro Oncol. 2022;24:v1-v95. doi: 10.1093/neuonc/noac202
2. Li D, Chen Y, Wong TF, et al. Management and survival trends for diffuse gliomas diagnosed at a single neurooncology center in China during 2000 to 2020. Sci Rep. 2025;15:12574. doi: 10.1038/s41598-025-95693-5
3. Alexander BM, Cloughesy TF. Adult Glioblastoma. J Clin Oncol. 2017;35:2402-2409. doi: 10.1200/JCO.2017.73.0119
4. Liang BC, Thornton AF, Sandler H, Greenberg H. Malignant Astrocytoma: Focal tumor recurrence after focal external beam radiation therapy. J Neurosurg. 1991;75:559-563. doi: 10.3171/jns.1991.75.4.0559
5. Touat M, Li YY, Boynton AN, et al. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature. 2020;580(7804):517-523. doi: 10.1038/s41586-020-2209-9
6. Badani A, Ozair A, Khasraw M, et al. Immune checkpoint inhibitors for glioblastoma: emerging science, clinical advances, and future directions. J Neurooncol. 2025;171(3):531-547. doi: 10.1007/s11060-024-04881-2
7. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23:1231-1251. doi: 10.1093/neuonc/noab106
8. Brentlinger MN, Patel J, Khan A, et al. Diffuse pediatric-type high grade glioma, RTK1 subtype, subclass C with SYN2 :: PPARG fusion in an older adult. CNS Oncol. 2026;15(1):2641996. doi: 10.1080/20450907.2026.2641996
9. Cheaney B, Wood MD, Szidonya L, et al. Remarkable response to radiation in a non-enhancing diffuse pediatric-type high-grade glioma with germline ATM mutation: The role of PET imaging and integrated histological and molecular analysis. Neuro Oncol Adv. 2026;8(1):vdag059. doi: 10.1093/noajnl/vdag059
10. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997-1003. doi: 10.1056/NEJMoa043331
11. Binabaj MM, Bahrami A, ShahidSales S, et al. The prognostic value of MGMT promoter methylation in glioblastoma: a meta-analysis of clinical trials. J Cell Physiol. 2018;233(1):378-386. doi: 10.1002/jcp.25896
12. Cohen AL, Holmen SL, Colman H. IDH1 and IDH2 Mutations in Gliomas. Curr Neurol Neurosci Rep. 2013;13(5):345. doi: 10.1007/s11910-013-0345-4
13. Eid M, Alset D, Timoshkina N, et al. IDH mutation and MGMT methylation status in glioblastoma and other gliomas patients: a Russian retrospective cohort study. J Egypt Natl Cancer Inst. 2025;37(1):36. doi: 10.1186/s43046-025-00296-w
14. An Z, Aksoy O, Zheng T, Fan QW, Weiss WA. Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene. 2018;37(12):1561-1575. doi: 10.1038/s41388-017-0045-7
15. Fortin Ensign SP, Jenkins RB, Giannini C, Sarkaria JN, Galanis E, Kizilbash SH. Translational significance of CDKN2A/B homozygous deletion in isocitrate dehydrogenase-mutant astrocytoma. Neuro Oncol. 2023;25(1):28-36. doi: 10.1093/neuonc/noac205
16. Yuan F, Wang Y, Yuan L, et al. EGFRvIII-positive glioblastoma contributes to immune escape and malignant progression via the c-Fos-MDK-LRP1 axis. Cell Death Dis. 2025;16(1):453. doi: 10.1038/s41419-025-07771-1
17. Tang S, Zhou Q, Bergholz JS, et al. PTEN Loss Promotes PI3Kβ Phosphorylation and EPHA2/SRC/p-PI3KβY962 Complex Assembly to Drive Tumorigenesis. Cancer Discov. 2026;16:521-540. doi: 10.1158/2159-8290.CD-25-1126
18. Solomon DA, Wood MD, Tihan T, Bollen AW, Gupta N, Phillips JJ, Perry A. Diffuse Midline Gliomas with Histone H3-K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations. Brain Pathol. 2016;26(5):569-580. doi: 10.1111/bpa.12336
19. Aldape K, Brindle KM, Chesler L, et al. Challenges to curing primary brain tumours. Nat Rev Clin Oncol. 2019;16(8):509- 520. doi: 10.1038/s41571-019-0177-5
20. Gong G, Jiang L, Zhou J, Su Y. Advancements in targeted and immunotherapy strategies for glioma: toward precision treatment. Front Immunol. 2025;15:1537013. doi: 10.3389/fimmu.2024.1537013
21. Al Sharie S, Sawaftah K, Qasim H, Al-Hussaini M. Methylation profiling in neuropathological tumors diagnosis: a comprehensive review. Front Oncol. 2025;15:1720458. doi: 10.3389/fonc.2025.1720458
22. Moosa E, Alanany R, Sherif S, et al. Enhancing the accuracy of molecular classification of pediatric CNS tumors: a dual-classifier approach using DNA methylation profiling. Front Oncol. 2026;15:1701113. doi: 10.3389/fonc.2025.1701113
23. Guo S, Sidhu R, Ramar V, Guo AA, Wang G, Liu M. RNA Sequencing Identifies Novel Signaling Pathways and Potential Drug Target Genes Induced by FOSL1 in Glioma Progression and Stemness. Biologics. 2025;19:157-176. doi: 10.2147/BTT.S509774
24. Eibl RH, Schneemann M. Liquid biopsy and glioblastoma. Explor Target Anti-Tumor Ther. 2023;4(1):28- 41. doi: 10.37349/etat.2023.00121
25. Mellinghoff IK, van den Bent MJ, Blumenthal DT, et al. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. N Engl J Med. 2023;389(7):589-601. doi: 10.1056/NEJMoa2304194
26. Pham J, Cote DJ, Kang K, et al. Treatment practices and survival outcomes for IDH-wildtype glioblastoma patients according to MGMT promoter methylation status: insights from the U.S. National Cancer Database. J Neurooncol. 2025;172(3):655-665. doi: 10.1007/s11060-025-04952-y
27. Kizilbash SH. Why has targeting EGFR aberrations in glioblastoma therapy had limited success? Expert Rev Anticancer Ther. 2022;22(12):1261-1263. doi: 10.1080/14737140.2022.2146581
28. Kaley T, Touat M, Subbiah V, et al. BRAF inhibition in BRAFV600E-mutant gliomas: results from the VE-BASKET study. J Clin Oncol. 2018;36(35):3477-3484. doi: 10.1200/JCO.2018.78.9990
29. Nobre L, Zapotocky M, Ramaswamy V, et al. Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition. JCO Precis Oncol. 2020;4:PO.19.00298. doi: 10.1200/PO.19.00298
30. Omuro A, Vlahovic G, Lim M, et al. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. Neuro Oncol. 2018;20(5):674-686. doi: 10.1093/neuonc/nox208
31. Schonfeld E, Choi J, Tran A, Kim LH, Lim M. The landscape of immune checkpoint inhibitor clinical trials in glioblastoma: A systematic review. Neurooncol Adv. 2024;6(1):vdae174. doi: 10.1093/noajnl/vdae174
32. Reardon DA, Brandes AA, Omuro A, et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020;6(7):1003-1010. doi: 10.1001/jamaoncol.2020.1024
33. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996. doi: 10.1056/NEJMoa043330
34. Ringel F, Pape H, Sabel M, et al. Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection. Neuro Oncol. 2016;18(1):96- 104. doi: 10.1093/neuonc/nov145
35. Gerritsen JKW, Broekman MLD, De Vleeschouwer S, et al. Safe surgery for glioblastoma: Recent advances and modern challenges. Neurooncol Pract. 2022;9(5):364-379. doi: 10.1093/nop/npac019
36. American Society for Radiation Oncology. ASTRO updates guideline on radiation therapy for high-grade diffuse glioma, the most common primary brain tumor in adults. June 26, 2025. Available from: https://www.astro.org/news-and-publications/news-and-media-center/news-releases/2025/ astro-updates-guideline-on-radiation-therapy-for-high-grade-diffuse-glioma [Last accessed on November 1, 2025].
37. Fernández C, Ciérvide R, Díaz A, Garrido I, Couñago F. Radiotherapy in Glioblastoma Multiforme: Evolution, Limitations, and Molecularly Guided Future. Biomedicines. 2025;13(9):2136. doi: 10.3390/biomedicines13092136
38. Khagi S, Kotecha R, Gatson NTN, et al. Recent advances in Tumor Treating Fields (TTFields) therapy for glioblastoma. Oncologist. 2025;30(2):oyae227. doi: 10.1093/oncolo/oyae227
39. Kinzel A, Ambrogi M, Varshaver M, Kirson ED. Tumor Treating Fields for glioblastoma treatment: patient satisfaction and compliance with the second-generation Optune system. Clin Med Insights Oncol. 2019;13:1179554918825449. doi: 10.1177/1179554918825449
40. Stepanenko AA, Sosnovtseva AO, Valikhov MP, et al. The need for paradigm shift: prognostic significance and implications of standard therapy-related systemic immunosuppression in glioblastoma for immunotherapy and oncolytic virotherapy. Front Immunol. 2024;15:1326757. doi: 10.3389/fimmu.2024.1326757
41. Choi BD, Gerstner ER, Frigault MJ, et al. Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma. N Engl J Med. 2024;390(14):1290-1298. doi: 10.1056/NEJMoa2314390
42. Begley SL, O’Rourke DM, Binder ZA. CAR T cell therapy for glioblastoma: A review of the first decade of clinical trials. Mol Ther. 2025;33(6):2454-2461. doi: 10.1016/j.ymthe.2025.03.004
43. Bagley SJ, Logun M, Fraietta JA, et al. Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results. Nat Med. 2024;30(5):1320-1329. doi: 10.1038/s41591-024-02893-z
44. Czyżewski W, Kus-Budzynska K, Sobstyl J, et al. CAR-T cell therapy for glioblastoma: advances, challenges, and future directions. Ann Med Surg (Lond). 2025;87(9):5743-5756. doi: 10.1097/MS9.0000000000003607
45. Park S, Maus MV, Choi BD. CAR-T cell therapy for the treatment of adult high-grade gliomas. NPJ Precis Oncol. 2024;8(1):279. doi: 10.1038/s41698-024-00753-0
46. Li N, Rodriguez JL, Yin Y, et al. Armored bicistronic CAR T cells with dominant-negative TGF-β receptor II to overcome resistance in glioblastoma. Mol Ther. 2024;32(10):3522- 3538. doi: 10.1016/j.ymthe.2024.07.020
47. Su H, Peng Y, Wu Y, Zeng X. Overcoming immune evasion with innovative multi-target approaches for glioblastoma. Front Immunol. 2025;16:1541467. doi: 10.3389/fimmu.2025.1541467
48. Liau LM, Ashkan K, Brem S, et al. Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial. JAMA Oncol. 2023;9(1):112-121. doi: 10.1001/jamaoncol.2022.5370
49. Todo T, Ino Y, Ohtsu H, Shibahara J, Tanaka M. A phase I/II study of triple-mutated oncolytic herpes virus G47Δ in patients with progressive glioblastoma. Nat Commun. 2022;13(1):4119. doi: 10.1038/s41467-022-31262-y
50. Gállego Pérez-Larraya J, Garcia-Moure M, Labiano S, et al. Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma. N Engl J Med. 2022;386(26):2471-2481. doi: 10.1056/NEJMoa2202028
51. Russell L, Swanner J, Jaime-Ramirez AC, et al. PTEN expression by an oncolytic herpes simplex virus directs T-cell mediated tumor clearance. Nat Commun. 2018;9(1):5006. doi: 10.1038/s41467-018-07344-1
52. Ahluwalia MS, Reardon DA, Abad AP, et al. Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma. J Clin Oncol. 2023;41(7):1453- 1465. doi: 10.1200/JCO.22.00996
53. Huang B, Li X, Li Y, Zhang J, Zong Z, Zhang H. Current Immunotherapies for Glioblastoma Multiforme. Front Immunol. 2021;11:603911. doi: 10.3389/fimmu.2020.603911
54. Mao M, Yang W, Zhang X. Current mRNA-based vaccine strategies for glioma treatment. Crit Rev Oncol Hematol. 2024;202:104459. doi: 10.1016/j.critrevonc.2024.104459
55. Tripathy DK, Panda LP, Biswal S, Barhwal K. Insights into the glioblastoma tumor microenvironment: current and emerging therapeutic approaches. Front Pharmacol. 2024;15:1355242. doi: 10.3389/fphar.2024.1355242
56. Bova V, Filippone A, Casili G, et al. Adenosine Targeting as a New Strategy to Decrease Glioblastoma Aggressiveness. Cancers. 2022;14(16):4032. doi: 10.3390/cancers14164032
57. Liang BC, Grootveld M. The Importance of Mitochondria in Tumorigenesis: Glioma as the Paradigm (review). Int J Mol Med. 2011;27(2):159-171. doi: 10.3892/ijmm.2010.579
58. Ho RLY, Ho IAW. Recent Advances in Glioma Therapy: Combining Vascular Normalization and Immune Checkpoint Blockade. Cancers. 2021;13(15):3686. doi: 10.3390/cancers13153686
59. Trejo-Solis C, Silva-Adaya D, Serrano-García N, et al. Role of Glycolytic and Glutamine Metabolism Reprogramming on the Proliferation, Invasion, and Apoptosis Resistance through Modulation of Signaling Pathways in Glioblastoma. Int J Mol Sci. 2023;24(24):17633. doi: 10.3390/ijms242417633
60. ter Linden E, Abels ER, van Solinge TS, Neefjes J, Broekman MLD. Overcoming barriers in glioblastoma – Advances in drug delivery strategies. Cells. 2024;13(12):998. doi: 10.3390/cells13120998
61. Timbie KF, Mead BP, Price RJ. Drug and gene delivery across the blood–brain barrier with focused ultrasound. J Control Release. 2015;219:61-75. doi: 10.1016/j.jconrel.2015.08.059
62. Islam S, Ahmed MMS, Islam MA, Hossain N, Chowdhury MA. Advances in nanoparticles in targeted drug delivery–A review. Results Surf Interfaces. 2025;19:100529. doi: 10.1016/j.rsurfi.2025.100529
63. De Simone M, Conti V, Palermo G, De Maria L, Iaconetta G. Advancements in Glioma Care: Focus on Emerging Neurosurgical Techniques. Biomedicines. 2023;12(1):8. doi: 10.3390/biomedicines12010008
64. Korshoej AR, Lukacova S, Lassen-Ramshad Y, et al. OptimalTTF-1: Enhancing tumor treating fields therapy with skull remodeling surgery. A clinical phase I trial in adult recurrent glioblastoma. Neurooncol Adv. 2020;2(1):vdaa121. doi: 10.1093/noajnl/vdaa121
65. Eatz TA, Eichberg DG, Lu VM, Di L, Komotar RJ, Ivan ME. Intraoperative 5-ALA fluorescence-guided resection of high-grade glioma leads to greater extent of resection with better outcomes: a systematic review. J Neurooncol. 2022;156(2):233-256. doi: 10.1007/s11060-021-03901-9
66. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomized controlled multicentre phase III trial. Lancet Oncol. 2006;7(5):392-401. doi: 10.1016/S1470-2045(06)70665-9
67. Pirro V, Alfaro CM, Jarmusch AK, Hattab EM, Cohen- Gadol AA, Cooks RG. Intraoperative assessment of tumor margins during glioma resection by desorption electrospray ionization-mass spectrometry. Proc Natl Acad Sci USA. 2017;114(26):6700-6705. doi: 10.1073/pnas.1706459114
68. Hollon TC, Pandian B, Adapa AR, et al. Near real-time intraoperative brain tumor diagnosis using stimulated Raman histology and deep neural networks. Nat Med. 2020;26(1):52-58. doi: 10.1038/s41591-019-0715-9
69. Brown HM, Alfaro CM, Pirro V, et al. Intraoperative Mass Spectrometry Platform for IDH Mutation Status Prediction, Glioma Diagnosis, and Estimation of Tumor Cell Infiltration. J Appl Lab Med. 2021;6(4):902-916. doi: 10.1093/jalm/jfaa233
70. Hu LS, Smits M, Kaufmann TJ, et al. Advanced imaging in the diagnosis and response assessment of high-grade glioma: AJR Expert Panel Narrative Review. AJR Am J Roentgenol. 2025;224(1):e2330612. doi: 10.2214/AJR.23.30612
71. Patricoski-Chavez JA, Nagpal S, Singh R, Warner JL, Gamsiz Uzun ED. A deep learning model to predict glioma recurrence using integrated genomic and clinical data. Commun Med. 2025;5(1):359. doi: 10.1038/s43856-025-01083-3
72. Anwer MS, Abdel-Rasol MA, El-Sayed WM. Emerging therapeutic strategies in glioblastoma: drug repurposing, mechanisms of resistance, precision medicine, and technological innovations. Clin Exp Med. 2025;25(1):117. doi: 10.1007/s10238-025-01631-0
73. Xu C, Yuan X, Hou P, et al. Development of glioblastoma organoids and their applications in personalized therapy. Cancer Biol Med. 2023;20(5):353-368. doi: 10.20892/j.issn.2095-3941.2023.0061
74. Miller JJ, Cahill DP. MGMT promoter methylation and hypermutant recurrence in IDH mutant lower-grade glioma. Neuro Oncol. 2020;22(11):1553-1554. doi: 10.1093/neuonc/noaa212
75. Yang F, Yang P, Zhang C, et al. Stratification according to recursive partitioning analysis predicts outcome in newly diagnosed glioblastomas. Oncotarget. 2017;8(26):42974- 42982. doi: 10.18632/oncotarget.17322
76. Grant R, Liang BC, Page MA, Crane DL, Greenberg HS, Junck L. Age influences chemotherapy response in astrocytomas. Neurology. 1995;45(5):929-933. doi: 10.1212/WNL.45.5.929
77. Han Q, Liang H, Cheng P, Yang H, Zhao P. Gross Total vs. Subtotal Resection on Survival Outcomes in Elderly Patients With High-Grade Glioma: A Systematic Review and Meta- Analysis. Front Oncol. 2020;10:151. doi: 10.3389/fonc.2020.00151
78. Wick W. TTFields: Where does all the skepticism come from? Neuro Oncol. 2016;18(3):303-305. doi: 10.1093/neuonc/now012
79. Sipos D, Raposa BL, Freihat O, et al. Glioblastoma: Clinical Presentation, Multidisciplinary Management, and Long- Term Outcomes. Cancers. 2025;17(1):146. doi: 10.3390/cancers17010146
80. Wick W, Hartmann C, Engel C, et al. NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide. J Clin Oncol. 2009;27(35):5874-5880. doi: 10.1200/JCO.2009.23.6497
81. Yu X, Zhou J, Wu Y, et al. Assessment of MGMT promoter methylation status in glioblastoma using deep learning features from multi-sequence MRI of intratumoral and peritumoral regions. Cancer Imaging. 2024;24(1):172. doi: 10.1186/s40644-024-00817-1
82. McGrail DJ, Pilié PG, Rashid NU, et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol. 2021;32(5):661- 672. doi: 10.1016/j.annonc.2021.02.006
83. Amirmahani F, Kumar S, Muthukrishnan SD. Epigenetic mechanisms of plasticity and resistance in glioblastoma: therapeutic targets and implications. Front Epigenetics Epigenomics. 2025;3:1519449. doi: 10.3389/freae.2025.1519449
84. Brown NF, Ottaviani D, Tazare J, et al. Survival Outcomes and Prognostic Factors in Glioblastoma. Cancers. 2022;14(13):3161. doi: 10.3390/cancers14133161

85. Abdel Razek AAK, Alksas A, Shehata M, et al. Clinical applications of artificial intelligence and radiomics in neuro-oncology imaging. Insights Imaging. 2021;12(1):152. doi: 10.1186/s13244-021-01102-6